Ivermectin for Humans: Uses, Dosage & Safety Guide

Ivermectin's original human indication remains one of its most impactful. A single oral dose of 150 μg/kg kills microfilariae of Onchocerca volvulus and suppresses their production for months, preventing the inflammatory reactions that lead to blindness. Annual or semi-annual treatment has dramatically reduced the global burden of onchocerciasis, with several formerly endemic countries now certified as free of the disease (PMID: 25130507).

Ivermectin is the treatment of choice for intestinal strongyloidiasis caused by Strongyloides stercoralis. A single dose of 200 μg/kg achieves cure rates of 85-100%, superior to the alternative (thiabendazole) with far fewer side effects. For disseminated/hyperinfection strongyloidiasis — a life-threatening condition in immunocompromised patients — repeated doses may be necessary (PMID: 17488840).

Oral ivermectin (200 μg/kg, typically two doses 1–2 weeks apart) is effective for both ordinary and crusted (Norwegian) scabies. It is particularly valuable for institutional outbreaks, crusted scabies (which is refractory to topical treatments alone), and cases where topical application is impractical. The WHO included oral ivermectin on its Essential Medicines List for scabies treatment (PMID: 20573667).

In combination with albendazole (and sometimes diethylcarbamazine), ivermectin is a key component of mass drug administration programs targeting lymphatic filariasis. This triple-drug regimen can achieve >99% clearance of circulating microfilariae with a single dose, supporting the WHO's goal of eliminating lymphatic filariasis as a public health problem.

Additional approved or well-established uses include:

• Pediculosis (head lice) — topical 0.5% lotion (Sklice®)
• Rosacea — topical 1% cream (Soolantra®)
• Ascariasis, trichuriasis, and enterobiasis (off-label but supported by efficacy data)
• Demodex mite infestation — topical or oral

Dosage Guidelines by Indication

The following protocols are from the research literature and are NOT FDA-approved for cancer. They are presented for informational purposes only and should only be considered under medical supervision.

ISOM Protocol Component

The ISOM Protocol (Ivermectin + Fenbendazole + Mebendazole) represents a multi-target metabolic approach to cancer:

• Ivermectin component: 12–18 mg (approximately 0.2–0.4 mg/kg)
• Frequency: 1–3 times per week
• Timing: With a fatty meal (increases absorption 2.5×)
• Duration: Continuous or cycling schedules
• Combination rationale: Targets PAK1/Wnt (ivermectin) + microtubules (fenbendazole/mebendazole)
• Safety monitoring: Regular liver function tests and neurological assessment required

Clinical Trial NCT05318469 Dosing

The landmark Phase I/II trial at Cedars-Sinai investigating ivermectin + balstilimab (anti-CTLA-4) for metastatic triple-negative breast cancer uses:

• Dose: Oral ivermectin for 3 days every week
• Combined with: IV balstilimab every 3 weeks
• Duration: Up to 35 cycles (~2 years) or until progression
• Status: Preliminary data shows the combination is safe and well-tolerated with encouraging clinical benefit rates
• Results expected: Final report anticipated by end of 2026

How to Take Ivermectin Safely

• Take on an empty stomach with a full glass of water (standard recommendation)
• Take the full prescribed dose at once — do not split doses across the day
• Dose is always weight-based: weigh yourself accurately before calculating
• For scabies, a second dose 1–2 weeks later is standard practice
• Inform your healthcare provider of all concurrent medications

• Take with a high-fat meal — this increases absorption by approximately 2.5× (PMID: 12362927)
• Examples of fatty foods: avocado, full-fat yogurt, eggs cooked in butter, nuts, whole milk
• Follow your specific protocol's timing and frequency instructions exactly

• Alcohol: Both ivermectin and alcohol depress the CNS — avoid on dosing days
• Grapefruit juice: Inhibits CYP3A4, can increase ivermectin blood levels
• P-glycoprotein inhibitors: Certain medications can allow ivermectin into the brain (see Drug Interactions)

Using veterinary ivermectin paste intended for horses or livestock is strongly discouraged without medical guidance:

• Concentration issues: Horse paste contains 1.87% ivermectin (18.7 mg/g) — a single notch on the dispensing plunger delivers a dose intended for a 250 lb (113 kg) animal
• Excipient risks: Veterinary formulations contain excipients (inactive ingredients) not tested or approved for human consumption
• Dosing errors are common: Without precise weight-based calculations, overdosing with veterinary paste is easy and can lead to serious toxicity
• Case reports: Multiple cases of severe ivermectin toxicity have been reported following veterinary paste ingestion, including CNS depression, seizures, and hospitalization

Pharmacokinetics & Metabolism

Oral ivermectin is well absorbed from the gastrointestinal tract, with peak plasma concentrations achieved at approximately 4 hours post-dose. Bioavailability is estimated at approximately 60% under fasting conditions and significantly higher when administered with a high-fat meal (2.5-fold increase in AUC). The compound is highly lipophilic (logP = 3.2), which influences both its absorption characteristics and its tissue distribution (PMID: 12362927).

Ivermectin is extensively distributed throughout body tissues, with particular concentration in adipose tissue (which serves as a depot), liver, and skin. Plasma protein binding exceeds 93%, primarily to albumin. Importantly, ivermectin does not readily cross the blood-brain barrier (BBB) in mammals under normal conditions — this selective exclusion, mediated by P-glycoprotein (P-gp) efflux at the BBB, is a critical safety feature (PMID: 18446504).

Ivermectin is metabolized primarily by hepatic CYP3A4 enzymes, with minor contributions from CYP2D6 and CYP2E1. It undergoes extensive first-pass metabolism with formation of several hydroxylated metabolites. Key pharmacokinetic parameters:

• Terminal elimination half-life: ~18 hours (can extend to 28–36 hours due to redistribution from adipose tissue)
• Fecal excretion: >97% of the administered dose
• Urinary excretion: <1%
• Metabolism: Hepatic CYP3A4 (primary), CYP2D6, CYP2E1 (minor)
• Active metabolites: Several hydroxylated derivatives, some with residual activity

The long adipose tissue half-life has implications for both efficacy and safety. In parasitic disease treatment, it provides sustained exposure. For patients using ivermectin in off-label protocols, it means the drug accumulates with repeated dosing and requires careful dose spacing to avoid toxicity.

Safety Profile & Side Effects

Ivermectin's safety record is one of the most robust in pharmacology. Over 5 billion doses have been administered since 1987, primarily through mass drug administration programs in Africa, Latin America, and Southeast Asia. Serious adverse events are exceedingly rare when used at approved doses, and the compound has been administered safely to children as young as 5 years (≥15 kg body weight). This extraordinary track record contributed to its placement on the WHO Essential Medicines List and the 2015 Nobel Prize (PMID: 21321478).

Side effects are generally mild and often related to the inflammatory response triggered by parasite death (the "Mazzotti reaction" in onchocerciasis) rather than direct drug toxicity:

• Dizziness/lightheadedness: 2–3% of patients
• Nausea: 1–2%
• Diarrhea: 1–2%
• Pruritus (itching): Common in onchocerciasis treatment (Mazzotti reaction)
• Skin rash: Occasional, usually mild and self-limiting
• Fatigue: Transient in some patients
• Abdominal pain: Mild, typically resolves within 24–48 hours
• Myalgia: Occasional muscle aches, usually brief

Most side effects resolve within 24–48 hours without intervention. In mass drug administration programs, the incidence of adverse events requiring medical attention is less than 1 in 10,000 treated individuals.

Serious adverse events are rare but include:

• Severe Mazzotti reactions: In heavily infected onchocerciasis patients — may require corticosteroid management
• Encephalopathy: In patients with high Loa loa microfilaremia (>8,000 mf/mL) — a specific contraindication in endemic areas
• Neurotoxicity: In individuals with P-glycoprotein deficiency or disrupted BBB (see MDR1 section below)
• Hepatotoxicity: Very rare; mild transaminase elevations reported with extended use
• Stevens-Johnson syndrome: Extremely rare, case reports only

These events are largely predictable and preventable through appropriate patient screening. The risk of serious adverse events increases with higher doses, repeated administration, and in patients with compromised P-glycoprotein function.

The MDR1 Gene: Why It Matters for Ivermectin Safety

The MDR1 gene (ABCB1) encodes P-glycoprotein, an ATP-dependent efflux transporter that serves as a critical gatekeeper at the blood-brain barrier. Understanding this gene is essential for anyone considering ivermectin use, particularly at higher or repeated doses (PMID: 14975065).

Under normal conditions, P-glycoprotein actively pumps ivermectin out of the central nervous system before it can accumulate to toxic levels. This efflux mechanism is the primary reason ivermectin is safe for mammals despite its potent neurotoxic effects on invertebrates. In laboratory studies with P-glycoprotein knockout mice, brain concentrations of ivermectin were 36–60 times higher than in normal mice — demonstrating the critical importance of this protective system (PMID: 19161460).

While the dramatic P-glycoprotein deficiency seen in certain dog breeds (particularly collies with the 4-base pair mdr1 deletion) has not been identified in humans, numerous single nucleotide polymorphisms (SNPs) in the human ABCB1 gene have been documented. Current evidence suggests that common human ABCB1 haplotypes generally maintain adequate blood-brain barrier functionality, but reduced P-glycoprotein expression or activity could theoretically increase vulnerability (PMID: 17354009).

• Drug interactions: Co-administration with P-gp inhibitors (see Drug Interactions)
• Compromised blood-brain barrier: Brain tumors, meningitis, recent cranial surgery, or head trauma
• High doses: Risk increases significantly above approved dosing ranges
• Very young or elderly: Immature or deteriorating BBB function
• Genetic variants: While not as well-characterized as in veterinary medicine, individual variation in P-gp expression exists

Symptoms progress from mild to severe:

• Mild: Dizziness, confusion, drowsiness, visual disturbances
• Moderate: Ataxia (difficulty walking), tremors, disorientation
• Severe: Seizures, respiratory depression, coma

If any neurological symptoms occur after taking ivermectin, discontinue immediately and seek emergency medical care. There is no specific antidote; treatment is supportive.

• Consider genetic testing for ABCB1 variants before starting long-term ivermectin protocols
• Always start with lower doses and increase gradually ("start low, go slow")
• Ensure medical supervision for any off-label or research protocol use
• Report any neurological symptoms immediately
• Review all concurrent medications for potential P-gp interactions

Drug Interactions

As a CYP3A4 substrate, ivermectin levels may be significantly affected by other drugs that modulate this enzyme:

CYP3A4 inhibitors (may INCREASE ivermectin levels):

• Ketoconazole, itraconazole, voriconazole (antifungals)
• Ritonavir, cobicistat (HIV antivirals)
• Clarithromycin, erythromycin (macrolide antibiotics)
• Grapefruit juice (significant increase at regular consumption)
• Diltiazem, verapamil (calcium channel blockers)

CYP3A4 inducers (may DECREASE ivermectin levels):

• Rifampin (antibiotic — potent inducer)
• Phenytoin, carbamazepine (anticonvulsants)
• St. John's Wort (herbal supplement)
• Dexamethasone (at high doses)

Drugs that inhibit P-gp may increase ivermectin distribution to the CNS, theoretically increasing the risk of neurotoxicity. This is the most clinically significant interaction category:

• Verapamil, quinidine, amiodarone (cardiovascular drugs)
• Cyclosporine (immunosuppressant)
• Ketoconazole (dual CYP3A4 + P-gp inhibitor)
• Ranolazine (antianginal)
• Dronedarone (antiarrhythmic)

This interaction is particularly relevant for patients using ivermectin in multi-drug cancer research protocols, where multiple compounds may be taken simultaneously. Similar drug interaction concerns apply to other repurposed drugs — see the fenbendazole liver safety guide for comparable considerations.

Case reports suggest ivermectin may enhance the anticoagulant effect of warfarin through CYP enzyme competition. Patients on warfarin should have their INR monitored more closely if ivermectin is co-administered. This interaction is clinically relevant for patients using ivermectin in cancer-related protocols alongside anticoagulant therapy.

While no direct pharmacokinetic interaction has been established, both ivermectin and alcohol can cause CNS depression. Avoidance of alcohol around dosing time is prudent, especially at higher doses or with repeated administration.

Contraindications & Precautions

• Known hypersensitivity to ivermectin or any excipient
• High-density Loa loa microfilaremia (>8,000 mf/mL) — risk of fatal encephalopathy
• Children weighing less than 15 kg (limited safety data)

• Pregnancy (FDA Category C) — teratogenic in animal studies at high doses; use only when clearly needed
• Breastfeeding — ivermectin is excreted in breast milk; risk-benefit assessment required
• Severe hepatic impairment — potential for altered metabolism and accumulation
• CNS disorders or compromised BBB — increased risk of neurotoxicity
• Concurrent P-gp inhibitors — increased risk of CNS accumulation
• Elderly patients — may have reduced P-gp function and altered hepatic metabolism

Global-Scale Impact: Billions of Doses Distributed

Ivermectin's significance extends far beyond individual prescriptions. Since the World Health Organization launched the Global Programme to Eliminate Lymphatic Filariasis (GPELF) in 2000, more than 9.7 billion cumulative treatments have been administered worldwide to interrupt parasite transmission — the majority involving ivermectin-based regimens.

The drug's global reach is made possible in part by Merck's Mectizan Donation Program, initiated in 1987, which committed to supplying ivermectin free of charge "for as long as needed" to combat river blindness. This program remains one of the most successful public-private health partnerships in history and has since expanded to include lymphatic filariasis elimination.

By 2018, the number of people infected with lymphatic filariasis had declined by 74% compared to 2000, and 871 million people no longer required preventive chemotherapy. In sub-Saharan Africa, where onchocerciasis and lymphatic filariasis are frequently co-endemic, ivermectin-based mass drug administration (MDA) campaigns have been the cornerstone of elimination strategies for over two decades.

This extraordinary safety dataset — billions of supervised doses across diverse populations — provides a unique pharmacovigilance foundation. While these doses are given at standard antiparasitic levels (150–200 µg/kg), the accumulated evidence confirms that ivermectin at approved doses is remarkably well-tolerated in the general population, with serious adverse events occurring almost exclusively in patients with heavy Loa loa co-infection or MDR1 gene variants.

Topical Ivermectin: Soolantra and Dermatological Uses

Beyond oral tablets, ivermectin is also available as a topical formulation for dermatological conditions. In December 2014, the FDA approved Soolantra (ivermectin 1% cream) for the once-daily treatment of inflammatory lesions associated with rosacea — making it the first ivermectin product specifically approved for a skin condition in the United States.

In two Phase 3 clinical trials involving 1,371 adults with moderate-to-severe papulopustular rosacea, ivermectin 1% cream demonstrated significantly superior results compared to vehicle (placebo) cream. Between 38–40% of patients achieved "clear" or "almost clear" skin on the Investigator Global Assessment scale, compared to 12–19% in the control group. Significant improvement was observed as early as two weeks.

Topical ivermectin is also used off-label for:

• Demodex mite infestations — the antiparasitic mechanism directly targets Demodex folliculorum and D. brevis, which are implicated in many rosacea presentations.
• Head lice (pediculosis) — Sklice (ivermectin 0.5% lotion) was FDA-approved in 2012 for single-application treatment of head lice in patients 6 months and older.

These topical applications are pharmacokinetically distinct from oral dosing. Systemic absorption from ivermectin cream is minimal — plasma levels after topical application are roughly 100-fold lower than after standard oral doses — meaning the drug interaction and safety considerations described elsewhere in this article apply primarily to oral formulations.

Regulatory Landscape: How Access Varies Globally

Ivermectin's regulatory status varies significantly by country, creating a patchwork of access that directly affects patients seeking the medication.

Regardless of local regulatory status, the critical distinction remains: ivermectin is approved globally for parasitic infections. It has no regulatory approval for cancer treatment in any country. Any oncology-related use is experimental and off-label, requiring appropriate medical supervision.

Special Populations: Children, Elderly, and Compromised Patients

While ivermectin's safety in healthy adults is well-established, certain populations require additional caution.

The FDA label historically restricts ivermectin use to children weighing ≥15 kg (33 lbs). However, this threshold was based on limited early data rather than evidence of harm. A 2021 systematic review of 1,088 children under 15 kg found only 1.4% experienced adverse events — all mild and self-limiting, with no serious events reported (PLoS NTD, PMID: 33471839). Pharmacokinetic modeling suggests age-appropriate dosing (0.75 mg for 3–7 months, 1.5 mg for 8–12 months, 3 mg for 13–24 months) can achieve equivalent exposure, though these doses await formal clinical trial validation.

No specific dose adjustment is recommended for elderly patients. However, age-related decline in hepatic CYP3A4 activity and renal function may alter drug clearance. Polypharmacy — common in elderly populations — increases the risk of drug interactions, particularly with CYP3A4 inhibitors (see Drug Interactions section above). Liver function monitoring is advisable in older adults taking ivermectin repeatedly.

Ivermectin is classified as Pregnancy Category C by the FDA — animal studies at high doses showed teratogenic effects, but no adequate studies exist in pregnant women. WHO guidelines exclude pregnant women from MDA campaigns during the first trimester. Ivermectin is excreted in breast milk in low concentrations; the WHO considers it compatible with breastfeeding when used at standard antiparasitic doses, but caution is advised for repeated or high-dose use.

Because ivermectin is extensively metabolized by hepatic CYP3A4, patients with significant liver disease may experience higher plasma levels and prolonged drug exposure. No formal pharmacokinetic studies exist in patients with hepatic impairment, but clinical caution is warranted — especially relevant for patients considering ivermectin alongside fenbendazole, as both compounds are hepatically processed. Ivermectin undergoes minimal renal excretion, so renal impairment alone does not typically necessitate dose adjustment.

Formulation Quality: How to Verify What You're Taking

The distinction between pharmaceutical-grade and veterinary ivermectin products cannot be overstated. Unlike Panacur C fenbendazole (which contains ~77.8% undisclosed excipients formulated for dogs), human ivermectin tablets are manufactured under strict GMP standards with precise active ingredient content.

Pharmaceutical-grade ivermectin tablets are available in 3 mg, 6 mg, and 12 mg strengths from multiple WHO-GMP certified manufacturers. When verifying product quality, confirm:

• Manufacturer name and GMP certification — legitimate products will list a licensed pharmaceutical manufacturer (e.g., Edenbridge, Mankind Pharma, Sun Pharma).
• USP or equivalent pharmacopoeia compliance — look for USP (United States Pharmacopeia) or equivalent quality standard on the labeling.
• Correct active ingredient and strength — the label should specify "ivermectin" as the only active ingredient, with a defined mg strength.
• Lot number and expiration date — all pharmaceutical products must carry batch identification and shelf-life information.
• No veterinary labeling — products labeled "for animal use only," "horse paste," or "cattle injectable" are NOT formulated for human consumption, regardless of the active ingredient being ivermectin.

Veterinary ivermectin paste (commonly sold as "horse dewormer") is formulated with excipients designed for equine palatability and gut transit — not for human absorption profiles. Concentration differences also create serious dosing errors: horse paste typically contains 1.87% ivermectin (18.7 mg/gram), making accurate human dosing with a syringe dispenser extremely imprecise.

Emerging Cancer Research: Current Evidence

The anticancer potential of ivermectin has become one of the most active areas of drug repurposing research. As detailed in the mechanism section, multiple independent studies have identified diverse anticancer mechanisms. However, it is essential to understand where the evidence currently stands.

The Phase I/II randomized controlled trial NCT05318469 at Cedars-Sinai Medical Center represents the most significant step toward clinical validation of ivermectin's anticancer potential. Key details:

• Design: Phase I/II, open-label, multi-cohort
• Population: Adults with metastatic triple-negative breast cancer (mTNBC), 1–2 prior lines of therapy
• Intervention: Oral ivermectin + IV balstilimab (anti-CTLA-4)
• Expansion cohorts: Specifically targeting PD-L1 negative tumors to investigate immune sensitization
• Primary endpoints: Safety, tolerability, recommended Phase II dose
• Secondary endpoints: Objective response rate, progression-free survival, biomarker analysis
• Preliminary results: ASCO 2025 abstract reported the combination is well-tolerated with encouraging clinical benefit rates in heavily pretreated patients
• Final results: Expected by end of 2026

For a detailed analysis of this trial's design, scientific rationale, and potential implications, see our dedicated article: Can Ivermectin Enhance Immunotherapy? Inside Trial NCT05318469.

Cancer Research: What Patients Should Know

Ivermectin has attracted significant scientific attention for potential anticancer properties. Here is what the evidence currently shows.

The most significant step toward clinical validation is the Phase I/II trial at Cedars-Sinai investigating ivermectin combined with immunotherapy (balstilimab) for metastatic triple-negative breast cancer. Preliminary data shows the combination is well-tolerated with encouraging clinical benefit. Final results are expected by end of 2026.

• Lab studies (in vitro): Multiple anticancer mechanisms confirmed ✅
• Animal models: Tumor suppression demonstrated ✅
• Human clinical trials: Phase I/II ongoing
• FDA approval for cancer: None ❌

Bottom line: Ivermectin is NOT a proven cancer treatment. The research is scientifically promising but still experimental. Never replace standard oncological care with ivermectin. Always discuss with your oncologist first.

Where to Get Ivermectin

In most countries, pharmaceutical-grade ivermectin for human use requires a prescription. Available formulations include oral tablets (Stromectol® and generics in 3 mg, 6 mg, 12 mg), topical cream 1% (Soolantra® for rosacea), and topical lotion 0.5% (Sklice® for head lice).

• ✅ Certificate of Analysis (COA) — confirms purity and potency through independent lab testing
• ✅ GMP manufacturing — Good Manufacturing Practices certification
• ✅ Proper labeling — lot number, expiration date, manufacturer information
• ✅ Reputable source — licensed pharmacy or verified supplier with track record

For guidance on evaluating pharmaceutical suppliers, see our quality verification guide.

When to Call Your Doctor

• Seizures or convulsions
• Difficulty breathing or shortness of breath
• Loss of consciousness
• Severe confusion or inability to recognize people
• Severe allergic reaction (face/throat swelling, hives)

• Persistent dizziness, confusion, or drowsiness lasting more than 24 hours
• Visual disturbances (blurred vision, seeing double)
• Difficulty walking or loss of balance
• Tremors or involuntary muscle movements
• Dark urine or yellowing of skin/eyes (possible liver problems)
• Severe Mazzotti reaction symptoms (high fever, severe joint pain, facial swelling)

• Mild side effects lasting more than 48 hours
• Questions about drug interactions with new medications
• Interest in using ivermectin for off-label purposes
• Planning pregnancy while taking ivermectin

Ivermectin Brand Names: Stromectol, Soolantra, Sklice & Ivomec

Ivermectin is sold under several brand names depending on the formulation and whether it is intended for humans or animals. Understanding the difference is important for safety — some of the most-searched brand names (such as Ivomec) are veterinary products that should never be used by people.

Human ivermectin brands

Stromectol® is the best-known oral human formulation, available as 3 mg, 6 mg and 12 mg tablets, with numerous generic equivalents worldwide. For skin conditions, Soolantra® (ivermectin 1% cream) is FDA-approved for rosacea, and Sklice® (0.5% lotion) treats head lice. These are pharmaceutical-grade products manufactured to human safety standards. See our dosage guidelines and topical formulations sections for details.

Why people search “Ivomec for humans” — and why it is a mistake

Ivomec® is a veterinary brand of ivermectin made for livestock (cattle, swine, horses). It is one of the most commonly searched terms because the veterinary product is often cheaper and available without a prescription. However, veterinary ivermectin is not appropriate for human use: concentrations are formulated for animals many times the weight of a person, injectable and pour-on products contain carriers and excipients never tested for human safety, and there is no certificate of analysis verifying human-grade purity. Dosing errors with concentrated veterinary paste and pour-on solutions are a leading cause of ivermectin overdose reports. If you need ivermectin, use a pharmaceutical human formulation obtained through a licensed pharmacy — see Where to Get Ivermectin and our quality verification guide.

Practical Guidance for Patients

• For FDA-approved indications: take as a single dose on an empty stomach with water (unless your protocol specifies otherwise)
• For oncology research protocols: take with a high-fat meal for enhanced absorption (2.5× increase)
• Standard tablets available in 3 mg, 6 mg, and 12 mg strengths
• Dose is weight-based (150–200 μg/kg depending on indication)
• For scabies, a second dose 1–2 weeks later is standard
• Inform your healthcare provider of all concurrent medications
• Avoid alcohol around the time of dosing

For single-dose parasitic treatment: routine monitoring is generally unnecessary.

For repeated/off-label use (such as cancer protocols):

• Complete blood count (CBC) — baseline and quarterly
• Liver function tests (AST, ALT, bilirubin) — quarterly
• Renal function (creatinine, BUN) — quarterly
• Neurological symptom monitoring — ongoing
• INR if on anticoagulants — more frequent monitoring
• Consider ABCB1 genetic testing before long-term protocols

Report any neurological symptoms (confusion, difficulty walking, vision changes) immediately. For a detailed discussion of monitoring during repurposed drug protocols, see the fenbendazole dosage guide which covers similar considerations.

• Store at room temperature (20–25°C / 68–77°F)
• Protect from moisture and light
• Stable for 2–3 years under proper storage conditions
• Do not crush or divide tablets unless specifically formulated for this
• Global-Scale Impact: Billions of Doses Distributed
• Topical Ivermectin: Soolantra and Dermatological Uses
• Regulatory Landscape: How Access Varies Globally
• Special Populations: Children, Elderly, and Compromised Patients
• Formulation Quality: How to Verify What You're Taking
• Keep out of reach of children

Frequently Asked Questions

In humans, ivermectin is FDA-approved to treat several parasitic infections: onchocerciasis (river blindness), strongyloidiasis (intestinal threadworm), and — as topical formulations — rosacea (Soolantra® cream) and head lice (Sklice® lotion). It is also used off-label and in some countries for scabies and lymphatic filariasis. Beyond approved uses, ivermectin is being studied experimentally in oncology, but it is not approved for cancer. See the What Is Ivermectin? section for the full list of indications.

For scabies, oral ivermectin is typically dosed at 200 μg/kg body weight as a single dose, often repeated after 7–14 days to kill mites that hatch from eggs after the first dose. For a 70 kg adult this is roughly 12–15 mg per dose. Crusted (Norwegian) scabies may require additional doses combined with topical treatment. Dosing should always be confirmed by a clinician — see the Weight-Based Dosing Chart for exact figures by body weight.

Yes. Soolantra® is a topical ivermectin 1% cream FDA-approved in 2014 for the inflammatory lesions of rosacea. In Phase 3 trials, 38–40% of patients achieved clear or almost-clear skin. It works through both anti-inflammatory action and by targeting Demodex mites implicated in rosacea. Systemic absorption from the cream is minimal, so its safety profile differs from oral tablets. See Topical Ivermectin for details.

Ivomec® is a veterinary brand of ivermectin formulated for livestock (cattle, swine, horses) as injectables, oral drenches and pour-on solutions. Human ivermectin (e.g., Stromectol®) is manufactured to pharmaceutical standards with verified purity and human-appropriate dosing. Veterinary products are concentrated for animals weighing hundreds of kilograms and contain carriers never tested for human safety, making accurate and safe dosing in people extremely difficult. Ivomec and other veterinary formulations should not be used by humans — see Ivermectin Brand Names.

In most countries, oral pharmaceutical ivermectin for human use requires a prescription. Availability varies: some nations sell it over the counter or through pharmacy programs, while topical Sklice® lotion for head lice is OTC in some markets. Regardless of where it is obtained, look for a certificate of analysis (COA), GMP manufacturing and proper labeling. See Where to Get Ivermectin for a quality checklist.